ADACEL QUADRA®
Suspension for Injection 1 x 0 5ml
registration number
42/30.1/0118
What ADACEL QUADRA® is and what it is used for
ADACEL QUADRA is indicated for active immunisation against diphtheria, tetanus, pertussis and poliomyelitis in persons aged 3 years and older as a booster dose following primary immunisation.
ADACEL QUADRA has been used in clinical studies in elderly persons aged 59 to 91 years of age.
Passive immunisation against pertussis in early infancy following maternal immunization during pregnancy (see sections 4.2, 4.4, 4.6 and 5.1).
Persons who have had pertussis, tetanus or diphtheria, should still be immunised since these clinical infections do not always confer immunity. Although well-documented pertussis disease is likely to confer immunity, the duration of protection is unknown.
ADACEL QUADRA is not to be used for the treatment of disease caused by B. pertussis, C. diphtheriae or C. tetani, or poliomyelitis infections.
HIV-infected persons, both asymptomatic and symptomatic, should be immunised against diphtheria, tetanus, pertussis and poliomyelitis according to standard schedules.
dosage
ADACEL QUADRA should be administered as a single injection of one dose (0,5 ml) by the intramuscular route.
ADACEL QUADRA should not be used for primary immunisation.
In adolescents and adults with an unknown or incomplete diphtheria or tetanus vaccination status against diphtheria or tetanus, one dose of ADACEL QUADRA can be administered as part of a vaccination series to protect against pertussis and poliomyelitis and in most cases also against tetanus and diphtheria. One additional dose of a diphtheria- and tetanus- (dT) containing vaccine can be administered one month later followed by a 3rd dose of a diphtheria or dT containing vaccine 6 months after the first dose to optimise protection against disease (see section 5.1). The number and schedule of doses should be determined according to local recommendations.
ADACEL QUADRA can be used for repeat vaccination to boost immunity to diphtheria, tetanus and pertussis at 5 to 10 year intervals (see section 5.1).
ADACEL QUADRA can be used in the management of tetanus prone injuries with or without concomitant administration of tetanus Immunoglobulin according to official recommendations.
ADACEL QUADRA may be administered to pregnant women during the second and third trimester to provide passive immunity to infants against pertussis (see sections 4.1, 4.4, 4.6 and 5.1).
how to take
Administer the vaccine intramuscularly. The preferred site is into the deltoid muscle. The vaccine should not be injected into the gluteal area. Do not administer ADACEL QUADRA intravenously.
The subcutaneous route should not be used (see section 4.4. for exceptions).
Fractional doses (doses < 0,5 ml) should not be given. The effect of fractional doses on the frequency of serious adverse events and on efficacy has not been determined.
For instructions on handling of ADACEL before administration, see section 6.6.
What ADACEL QUADRA® contains
Each dose (0,5 ml) contains:
Diphtheria toxoid* 2 Lf (not less than 2 IU)
Tetanus toxoid* 5 Lf (not less than 20 IU)
Pertussis toxoid (PT) 2,5 micrograms
Filamentous haemagglutinin (FHA) 5 micrograms
Fimbriae types 2 + 3 (FIM) 5 micrograms
Pertactin (PRN) 3 micrograms
Poliomyelitis virus type 1** (Mahoney) 40 D-antigen units
Poliomyelitis virus type 2** (MEF) 8 D-antigen units
Poliomyelitis virus type 3** (Saukett) 32 D-antigen units
* As lower confidence limit (p equals 0,95) of activity measured according to the assay described in the European Pharmacopoeia
** Produced on Vero cells
Sugar (glucose): trace amounts
ADACEL QUADRA contains, as residues from the manufacturing process, trace amounts of formaldehyde, glutaraldehyde, neomycin, streptomycin, polymyxin B and bovine serum albumin, as well as Hanks’ medium, a mixture of amino acids (including phenylalanine), salts, vitamins and other compounds (including glucose) (see sections 4.4 and 6.1).
other ingredients
Aluminium phosphate 1,5 mg (0,33 mg Al3+)
Phenoxyethanol not as preservative 3,3 mg (0,6 % v/v)
Ethanol 1,01 mg (0,3 % v/v)
Polysorbate 80 ≤ 0,01 % w/v
Water for injections.
Therapeutic classification
J07CA02.